WO2006114273A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
WO2006114273A3
WO2006114273A3 PCT/EP2006/003809 EP2006003809W WO2006114273A3 WO 2006114273 A3 WO2006114273 A3 WO 2006114273A3 EP 2006003809 W EP2006003809 W EP 2006003809W WO 2006114273 A3 WO2006114273 A3 WO 2006114273A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
vaccine
hpv16
immunization
vaccines
Prior art date
Application number
PCT/EP2006/003809
Other languages
French (fr)
Other versions
WO2006114273A2 (en
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecil Wettendorff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Priority claimed from US11/367,601 external-priority patent/US7858098B2/en
Priority to MX2007013475A priority Critical patent/MX2007013475A/en
Priority to EA200702077A priority patent/EA013325B1/en
Priority to JP2008508138A priority patent/JP2008539182A/en
Application filed by Glaxosmithkline Biolog Sa, Gary Dubin, Bruce Innis, Moncef Mohammed Slaoui, Martine Anne Cecil Wettendorff filed Critical Glaxosmithkline Biolog Sa
Priority to BRPI0610396-0A priority patent/BRPI0610396A2/en
Priority to AU2006239471A priority patent/AU2006239471A1/en
Priority to CA002606206A priority patent/CA2606206A1/en
Priority to EP06753410A priority patent/EP1879614A2/en
Publication of WO2006114273A2 publication Critical patent/WO2006114273A2/en
Publication of WO2006114273A3 publication Critical patent/WO2006114273A3/en
Priority to IL186591A priority patent/IL186591A0/en
Priority to NO20075185A priority patent/NO20075185L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention pertains to methods and vaccines for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV16 and HPV 18 virus like particles provides cross-protection against other HPV types.
PCT/EP2006/003809 2005-04-26 2006-04-24 Vaccine WO2006114273A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP06753410A EP1879614A2 (en) 2005-04-26 2006-04-24 Vaccine
CA002606206A CA2606206A1 (en) 2005-04-26 2006-04-24 Vaccine
AU2006239471A AU2006239471A1 (en) 2005-04-26 2006-04-24 Vaccine
EA200702077A EA013325B1 (en) 2005-04-26 2006-04-24 Vaccine
JP2008508138A JP2008539182A (en) 2005-04-26 2006-04-24 vaccine
MX2007013475A MX2007013475A (en) 2005-04-26 2006-04-24 Vaccine.
BRPI0610396-0A BRPI0610396A2 (en) 2005-04-26 2006-04-24 multivalent hpv vaccine, methods to protect a patient against infection, to prevent or reduce the frequency of cytological abnormalities in a patient, to prevent the formation of histologically confirmed lesions and to manufacture the vaccine, and, uses of a composition, to a vaccine and a vaccine composition
IL186591A IL186591A0 (en) 2005-04-26 2007-10-11 Vaccine
NO20075185A NO20075185L (en) 2005-04-26 2007-10-11 Vaccine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
US11/114,301 2005-04-26
EPPCT/EP2005/006461 2005-06-14
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US11/367,601 US7858098B2 (en) 2002-12-20 2005-12-16 Vaccine
US11/367,601 2005-12-16

Publications (2)

Publication Number Publication Date
WO2006114273A2 WO2006114273A2 (en) 2006-11-02
WO2006114273A3 true WO2006114273A3 (en) 2007-03-15

Family

ID=37199195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003809 WO2006114273A2 (en) 2005-04-26 2006-04-24 Vaccine

Country Status (12)

Country Link
EP (1) EP1879614A2 (en)
JP (1) JP2008539182A (en)
KR (1) KR20080005583A (en)
AR (1) AR053715A1 (en)
AU (1) AU2006239471A1 (en)
CA (1) CA2606206A1 (en)
EA (1) EA013325B1 (en)
MX (1) MX2007013475A (en)
NO (1) NO20075185L (en)
SG (1) SG159529A1 (en)
UY (1) UY29499A1 (en)
WO (1) WO2006114273A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147268A1 (en) * 2009-06-19 2010-12-23 아이진 주식회사 Vaccine for cervical cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097840A1 (en) * 2000-06-21 2001-12-27 Medimmune, Inc. Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
EP1410805A1 (en) * 1999-09-07 2004-04-21 GlaxoSmithKline Biologicals S.A. Vaccine against HPV
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410805A1 (en) * 1999-09-07 2004-04-21 GlaxoSmithKline Biologicals S.A. Vaccine against HPV
WO2001097840A1 (en) * 2000-06-21 2001-12-27 Medimmune, Inc. Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GIROGLOU T ET AL: "Immunological analyses of human papillomavirus capsids", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 13-14, 2001, pages 1783 - 1793, XP002248440, ISSN: 0264-410X *
GLAXOSMITHKLINE HPV VACCINE STUDY GROUP HARPER D M ET AL: "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 364, no. 9447, 13 November 2004 (2004-11-13), pages 1757 - 1765, XP004746625, ISSN: 0140-6736 *
REINIS MILAN: "Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL.", CURRENT OPINION IN MOLECULAR THERAPEUTICS. APR 2004, vol. 6, no. 2, April 2004 (2004-04-01), pages 206 - 211, XP009056594, ISSN: 1464-8431 *
RODEN R B S ET AL: "ASSESSMENT OF THE SEROLOGICAL RELATEDNESS OF GENITAL HUMAN PAPILLOMAVIRUSES BY HEMAGGLUTINATION INHIBITION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 5, May 1996 (1996-05-01), pages 3298 - 3301, XP002946729, ISSN: 0022-538X *
SAPP MARTIN ET AL: "Generation and applications of HPV pseudovirions using vaccinia virus.", METHODS IN MOLECULAR MEDICINE. 2005, vol. 119, 2005, pages 463 - 482, XP009074697, ISSN: 1543-1894 *
VILLA L L ET AL: "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 5, 7 April 2005 (2005-04-07), pages 271 - 278, XP004870902, ISSN: 1470-2045 *
WRIGHT T C ET AL: "Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts", VACCINE 21 AUG 2006 UNITED KINGDOM, vol. 24, no. SUPPL. 3, 21 August 2006 (2006-08-21), pages S251 - S261, XP009074690, ISSN: 0264-410X *

Also Published As

Publication number Publication date
KR20080005583A (en) 2008-01-14
UY29499A1 (en) 2006-11-30
MX2007013475A (en) 2008-04-02
AU2006239471A1 (en) 2006-11-02
JP2008539182A (en) 2008-11-13
AR053715A1 (en) 2007-05-16
SG159529A1 (en) 2010-03-30
WO2006114273A2 (en) 2006-11-02
EA200702077A1 (en) 2008-04-28
CA2606206A1 (en) 2006-11-02
EP1879614A2 (en) 2008-01-23
EA013325B1 (en) 2010-04-30
NO20075185L (en) 2008-01-25

Similar Documents

Publication Publication Date Title
EP4215543A3 (en) Hpv-specific binding molecules
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
CA2746228C (en) Modified rsv f proteins and methods of their use
EA201070794A1 (en) Recombinant antigens RSV
MX2012000035A (en) Recombinant rsv antigens.
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
IL203869A (en) Method for the manufcture of a preparation comprising virus or viral antigens and various aspects related thereto, uses thereof and a split virus vaccine preparation obtained by the method
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2008085147A3 (en) Novel plant virus particles and methods of inactivation thereof
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2007053446A3 (en) Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
FR15C0084I2 (en) VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52
HUS1500061I1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
BRPI0810951A2 (en) L1 hpv6 protein, polynucleotide, vector, cell, composition, virus-like particle (vlp) hpv6, method for producing an hpv l1 protein, vaccine for prevention of acuminate condyloma or porhpv infections, use of protein, method for prevention of condyloma acuminate or hpv infections, method for obtaining a vlp of an hpv6 l1 protein and method for producing a vaccine for the prevention of acuminate condyloma or hpv infections
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
MX2007013472A (en) Vaccine.
WO2006024240A3 (en) Vaccine composition against hepatitis c virus
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2005108560A3 (en) Synthesis and purification of west nile virus virus-like particles
WO2011100234A3 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
WO2006114273A3 (en) Vaccine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006239471

Country of ref document: AU

Ref document number: 186591

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 562525

Country of ref document: NZ

Ref document number: 3971/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2606206

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008508138

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12007502366

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/013475

Country of ref document: MX

Ref document number: 200680014223.7

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 07114258

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006239471

Country of ref document: AU

Date of ref document: 20060424

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006239471

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006753410

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2007000729

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1200702501

Country of ref document: VN

Ref document number: 1020077027492

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200702077

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06753410

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006753410

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0610396

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071026